How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
CRISPR And CRISPR-Associated Genes Market
- By CRISPR System Type: CRISPR-Cas9, CRISPR-Cas12, CRISPR-Cas13, CRISPR-Cas14, CRISPR-Cas3
- By Application: Gene Editing, Gene Regulation, Disease Modeling, Functional Genomics, Agricultural Biotechnology, Therapeutic Development
- By End User: Biotechnology Companies, Pharmaceutical Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Agricultural Biotechnology Firms
- By Product Type: CRISPR Kits and Reagents, CRISPR-associated Enzymes, CRISPR Vectors and Plasmids, CRISPR Delivery Systems, CRISPR Software and Bioinformatics Tools
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - CRISPR-Cas9 leads By CRISPR System Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.171 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the CRISPR And CRISPR-Associated Genes Market report
A complete, evidence-based study - 11 chapters and 120 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Editas Medicine Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →CRISPR Therapeutics AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Intellia Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Caribou Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mammoth Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Beam Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Synthego Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →ToolGen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →eGenesis Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cellectis S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Fate Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Verve Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Precision BioSciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Scribe Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Inscripta
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- CRISPR-Cas942.4
- CRISPR-Cas1212.7
- CRISPR-Cas1310.4
- CRISPR-Cas1413.0
- CRISPR-Cas321.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Editas Medicine Inc.8.9
- CRISPR Therapeutics AG28.3
- Intellia Therapeutics Inc.8.7
- Caribou Biosciences Inc.4.8
- Mammoth Biosciences Inc.10.4
- Beam Therapeutics Inc.10.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe22.5
- Asia Pacific21.9
- Latin America13.2
- Middle East and Africa8.8
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Editas Medicine Inc. | 89 | 78 | 99 | 79 | 80 | 94 | 87 |
| CRISPR Therapeutics AG | 70 | 71 | 77 | 74 | 73 | 70 | 73 |
| Intellia Therapeutics Inc. | 72 | 72 | 87 | 80 | 63 | 69 | 74 |
| Caribou Biosciences Inc. | 63 | 76 | 81 | 74 | 61 | 75 | 72 |
| Mammoth Biosciences Inc. | 52 | 61 | 58 | 71 | 64 | 74 | 63 |
| Beam Therapeutics Inc. | 52 | 67 | 69 | 66 | 63 | 52 | 62 |
| Synthego Corporation | 65 | 62 | 54 | 58 | 55 | 52 | 58 |
| ToolGen Inc. | 41 | 38 | 52 | 53 | 37 | 53 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Editas Medicine Inc.
- CRISPR Therapeutics AG
- Intellia Therapeutics Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Editas Medicine Inc. | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| CRISPR Therapeutics AG | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Intellia Therapeutics Inc. | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Caribou Biosciences Inc. | ◐ | ✓ | ◐ | ◐ | − | ✓ |
| Mammoth Biosciences Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Beam Therapeutics Inc. | − | − | − | − | ✓ | ◐ |
| Synthego Corporation | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| ToolGen Inc. | ◐ | − | − | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Challenger3
Strong scale, closing on the leaders.
Contender3
Focused players with pockets of strength.
Niche1
Specialists in a single segment or region.
Go-to-market strategy
Land CRISPR System Type in North America, then scale across CRISPR And CRISPR-Associated Genes Market — a $787M beachhead inside a $11.3B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →CRISPR-Cas9
Best fit — highest urgency & budget in CRISPR System Type.
CRISPR-Cas12
Strong fit — clear ROI and a fast path to value.
CRISPR-Cas13
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win CRISPR System Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For CRISPR System Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win CRISPR And CRISPR-Associated Genes Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
CRISPR And CRISPR-Associated Genes Market is a durable-growth opportunity — $2.61B by 2033, compounding at 8.8%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.8% CAGR
Demand compounds through 2033, outpacing GDP across CRISPR System Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in CRISPR System Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
CRISPR And CRISPR-Associated Genes Market — a $755M market by 2033. Plan: grow share from 10.6% to 16.4%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.6% | 16.4% | On track |
| Revenue | $79M | $124M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.8% | 43.7% | Ahead |
| Customer retention | 91.7% | 92.4% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in CRISPR System Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core CRISPR System Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $15M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for CRISPR System Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Sales deck · value proposition
Win the CRISPR And CRISPR-Associated Genes Market conversation — a $8.11B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of CRISPR System Type
Goal Grow share in CRISPR System Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your CRISPR And CRISPR-Associated Genes Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
CRISPR And CRISPR-Associated Genes Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →CRISPR and Cas Genes Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCrisper Related Nuclease Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportCRISPER-associated Nucleases Market
Market size, share, segmentation and regional forecast.
$441M market · 2025 base year
View reportCrisaborole API Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportBone Anchored Hearing Aids Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportCricothyrotomy Simulators Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportPPE Gloves Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportCrepe Bandage Market
Market size, share, segmentation and regional forecast.
$922M market · 2025 base year
View reportCremation Rollers Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCremation Diamonds Market
Cremation Diamonds Market is valued at USD 420 Million in 2025 and is expected to reach USD 760…
$420M market · 2025 base year
View reportProtective Gloves Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportCreatinine Urine Test Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy